The Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet)

0
64
Federal grants application on Grants.Gov

Funding Opportunity ID:310904
Opportunity Number:RFA-DD-19-002
Opportunity Title:The Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet)
Opportunity Category:Discretionary
Opportunity Category Explanation:
Funding Instrument Type:Cooperative Agreement
Category of Funding Activity:Health
Category Explanation:
CFDA Number(s):93.315
Eligible Applicants:State governments
County governments
City or township governments
Special district governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Small businesses
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility”
Additional Information on Eligibility:For an applicant to be considered they must be responsive to the information here. Component A – Core-Current: Applicants must document current funding under RFA DD-14-001 Surveillance and Research of Muscular Dystrophies and Neuromuscular Disorders. Component B – Core-New: Applicants must propose a study site that should be a specific geographic area with a population of at least 3 million people including a large minority population (e.g. African American, Asian, or Hispanic). Component C – Enhanced-Dissemination: Applicants must submit an application for Component A to apply for Component C. To be funded for Component C, the applicant must also be funded for Component A. Applicants should document that they have applied for Component A. Component D – Enhanced-DCC: Applicants must submit an application for Component A or B to apply for Component D. To be funded for Component D, the applicant must also be funded for Component A or B. Applicants should document that they have applied for Component A or B. Component E – Enhanced-Abstractor: Applicants must submit an application for Component A to apply for Component E. To be funded for Component E, the applicant must also be funded for Component A. Applicants should document that they have applied for Component A. If your application is incomplete or non-responsive to the special eligibility requirements listed in this section, it will not enter the review process.
Agency Code:HHS-CDC-HHSCDCERA
Agency Name:Department of Health and Human Services
Centers for Disease Control and Prevention – ERA
Posted Date:Dec 07, 2018
Close Date:Feb 13, 2019 Electronically submitted applications must be submitted no later than 5:00 p.m., ET, on the listed application due date.
Last Updated Date:Dec 07, 2018
Award Ceiling:$375,000
Award Floor:$0
Estimated Total Program Funding:$16,250,000
Expected Number of Awards:15
Description:The purpose of this NOFO is to better understand the public health and clinical impacts of living with MD by conducting longitudinal, population-based surveillance and research of eligible MDs (DMD, BMD, DM, FSHD, LGMD, CMD, EDMD, OPMD, and Distal MD). The current cycle will focus on identifying eligible MD cases, conducting longitudinal follow-up and research, analyzing data, and publishing and disseminating the results. Current MD STARnet sites will collect data to estimate prevalence and survival and additional clinical data on existing MD cohorts. New MD STARnet sites will focus on identifying eligible MD cases and collecting data to estimate prevalence, survival and track key clinical indicators. Identification of cases through population-based surveillance will enable existing and new sites to conduct research on these populations. This information is expected to advance understanding of diagnosed prevalence, disease progression and survival; clinical care and interventions and their alignment with recommended care; disparities in access to care; the association of treatment with outcomes, and the impact of MD on the lives of affected individuals and their families.
Version:1





Visit the Official Webpage For More Details on The Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet)